NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report published on Friday morning. The brokerage issued a hold rating on the stock.

NovaBay Pharmaceuticals Price Performance

Shares of NBY stock traded up $0.03 on Friday, reaching $0.75. 106,511 shares of the company were exchanged, compared to its average volume of 1,022,811. The company has a 50-day moving average of $0.59 and a 200-day moving average of $1.75. The company has a market cap of $3.67 million, a price-to-earnings ratio of -0.01 and a beta of 0.75. NovaBay Pharmaceuticals has a one year low of $0.36 and a one year high of $12.84.

NovaBay Pharmaceuticals (NYSE:NBY) last issued its earnings results on Tuesday, August 13th. The company reported ($1.37) earnings per share (EPS) for the quarter. The firm had revenue of $2.40 million during the quarter. NovaBay Pharmaceuticals had a negative return on equity of 744.33% and a negative net margin of 91.86%. As a group, sell-side analysts predict that NovaBay Pharmaceuticals will post -1.41 EPS for the current year.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.